ArticleProceedings of the National Academy of Sciences of the United States of America2020
Suboptimal SARS-CoV-2-specific CD8
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.Virus research · 2023Pooled it
- Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform.Cell reports. Medicine · 2021Pooled it
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.Current pharmaceutical biotechnology · 2026Article
- Alternative antigen retention by a gp96-fusion approach induces long-lasting and broad immunity in mice.Nature communications · 2025Article
- T-SCAPE: T cell immunogenicity scoring via cross-domain aided predictive engine.Science advances · 2025Article
- HLA-B*15:01-positive severe COVID-19 patients lack CD8Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Central memory T cells with key TCR repertoires and gene expression profiles dominate influenza CD8+ T cell pools across the human lifespan.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Differential reactivity of SARS-CoV-2 S-protein T-cell epitopes in vaccinated versus naturally infected individuals.Clinical & translational immunology · 2025Article
- Characterization of binding affinity changes of SARS-CoV-2 omicron variant peptides to population-specific HLA.Journal of biomedical science · 2025Article
- Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8European journal of immunology · 2025Article
- Bayesian Modeling of the Impact of HBOT on the Reduction in Cytokine Storms.Journal of clinical medicine · 2025Article
- Development of potent HLA-A02:01-restricted peptide-based cytotoxic T-cells against SARS-CoV-2 infections in patients awaiting a kidney transplant.Frontiers in immunology · 2025Article
- Features of Highly Homologous T-Cell Receptor Repertoire in the Immune Response to Mutations in Immunogenic Epitopes.International journal of molecular sciences · 2024Article
- Identification of virus epitopes and reactive T-cell receptors from memory T cells without peptide synthesis.Communications biology · 2024Article
- T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.Biomolecules · 2024Article
- SARS-CoV-2-specific CD8Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides.Journal for immunotherapy of cancer · 2024Article
- Scientific highlights of the 9th ESWI Influenza Conference.One health outlook · 2024Article
- The Influence of Cross-Reactive T Cells in COVID-19.Biomedicines · 2024Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 4 countries.
Jennifer R HabelDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0003-0380-1527
Thi H O NguyenDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-9294-7693
Carolien E van de SandtDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-4155-7433
Jennifer A JunoDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-9072-1017
Priyanka ChaurasiaInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-3755-159X
Kathleen WraggDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Marios KoutsakosDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-9994-9723
Luca HensenDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-8467-8537
Xiaoxiao JiaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Brendon ChuaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-5654-1293
Wuji ZhangDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Hyon-Xhi TanDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0003-1064-3934
Katie L FlanaganDepartment of Infectious Diseases, Launceston General Hospital, Launceston, TAS 7250, Australia.ORCID 0000-0002-1575-1953
Denise L DoolanCentre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD 4814, Australia.ORCID 0000-0001-7354-8817
Joseph TorresiDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Weisan ChenDepartment of Biochemistry and Genetics, La Trobe Institute of Molecular Science, La Trobe University, Bundoora 3084 VIC, Australia.ORCID 0000-0002-5221-9771
Linda M WakimDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Allen C ChengSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
Peter C DohertyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; pcd@unimelb.edu.au kkedz@unimelb.edu.au.
Jan PetersenInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Jamie RossjohnInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-2020-7522
Adam K WheatleyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-5593-9387
Stephen J KentDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-8539-4891
Louise C RowntreeDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-0649-5089
Katherine KedzierskaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; pcd@unimelb.edu.au kkedz@unimelb.edu.au.ORCID 0000-0001-6141-335X
The University of Melbourne · AUAustralian Research Council · AUAlfred Health · AUAustralian Institute of Tropical Health and Medicine · AUAustralian Regenerative Medicine Institute · AULa Trobe University · AUSt. Jude Children's Research Hospital · USUniversity of Tasmania · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
An improved understanding of human T cell-mediated immunity in COVID-19 is important for optimizing therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8
Indexed as
BetacoronavirusCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCoronavirus InfectionsCOVID-19Epitopes, T-LymphocyteFemaleHLA-A2 AntigenHumansImmunologic MemoryImmunophenotypingLeukocytes, MononuclearLymphocyte ActivationMaleMiddle AgedPandemicsEpitopes, T-LymphocyteHLA-A*02:01 antigenHLA-A2 AntigenORF1ab polyprotein, SARS-CoV-2Peptide FragmentsPolyproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral ProteinsCD8+ T cellsCOVID-19HLA-A*02:01SARS-CoV-2 epitopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.